Associated Genetic Biomarkers
TCF3-HLF Fusion is present in 0.03% of AACR GENIE cases, with breast invasive ductal carcinoma and esophageal adenocarcinoma having the greatest prevalence .
TCF3-HLF Fusion serves as an inclusion eligibility criterion in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain TCF3-HLF Fusion as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
Trials with TCF3-HLF Fusion in the inclusion eligibility criteria most commonly target B-cell acute lymphoblastic leukemia .
Cd19 chimeric antigen receptor t-cells is the most frequent therapy in trials with TCF3-HLF Fusion as an inclusion criteria .
Significance of TCF3-HLF Fusion in Diseases
B-Cell Acute Lymphoblastic Leukemia +
TCF3-HLF Fusion is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain TCF3-HLF Fusion and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.